TA-65 Clinical Research
TA-65 Clinical Research
TA-65, an Astragalus-derived telomerase activator, has been examined in published research. This page from RevGenetics summarizes two peer-reviewed studies in neutral, educational terms: a 2011 health maintenance program study in Rejuvenation Research, and Dr. Hector Valenzuela's 2013 laboratory work on telomerase activators in human T cells published in Cells. We report what the studies examined and make no health, longevity, or disease claims.
Published Research on a Natural Telomerase Activator
Interest in TA-65 is grounded in published research that has examined how a natural telomerase activator behaves in human studies and in laboratory cell models. On this page RevGenetics summarizes two peer-reviewed studies in neutral, educational terms. Our goal is to describe what each study set out to examine and what it reported, without claiming proven health or longevity outcomes and without making any disease claims.
This conservative framing is deliberate. Scientific studies in telomere biology investigate specific, measurable questions, such as whether an extract changes telomerase activity in cultured cells, or how a biomarker changes over time in participants following a program. Those are valuable observations, but they are not the same as demonstrating that a supplement treats a condition or extends lifespan, and we do not present them that way.
The 2011 Health Maintenance Program Study
One frequently referenced study is Harley, Liu, Blasco and colleagues, published in 2011 in the peer-reviewed journal Rejuvenation Research under the title "A Natural Product Telomerase Activator As Part of a Health Maintenance Program." The paper described a structured program that incorporated a natural product telomerase activator along with dietary supplementation and physician oversight, and it reported on measurements taken in participants, including telomere length and markers related to the immune system, over the course of the program.
Read accurately, the study is an account of what was measured within that program and how those measurements changed. RevGenetics reports this in neutral terms and does not interpret it as evidence that the activator slows or reverses aging or affects any disease.
Dr. Hector Valenzuela's Work on Telomerase Activators in T Cells
RevGenetics Chief Science Officer Dr. Hector Valenzuela, Ph.D., has academic research experience in this exact area. He co-authored a laboratory study published in the journal Cells in 2013, titled "Functional Assessment of Pharmacological Telomerase Activators in Human T Cells." The work examined how Astragalus-derived extracts affected telomerase activity in cultured human T cells, the immune cells that depend on the ability to divide many times to mount and sustain a response.
This is a cell-based, mechanistic study. It investigated whether and how the extracts influenced telomerase activity and the behavior of the cultured immune cells. As with the program study above, RevGenetics describes this research for educational purposes. A laboratory observation about telomerase activity in cultured cells is a scientific finding about cell biology, and it should not be read as a claim about treating, preventing, or curing any condition in people.
How to Read This Research Responsibly
Taken together, these publications show that TA-65 and the molecules associated with it have been the subject of genuine, peer-reviewed scientific inquiry, spanning both a human health maintenance program and controlled laboratory work in human immune cells. That reflects RevGenetics commitment, since 2007, to grounding its products in science.
Responsible reading also means recognizing the limits of what these studies establish. They examined telomerase activity, telomere length, and biomarkers; they did not prove anti-aging or disease outcomes, and we make no such claims. The featured TA-65 (25 mg) is the standardized 25 mg Astragalus-derived telomerase activator discussed in this research context. For background, see our guides on what telomerase is, telomere lengthening science, and the Astragalus source of TA-65.
References. Harley CB, Liu W, Blasco M, Vera E, Andrews WH, Briggs LA, Raffaele JM. "A Natural Product Telomerase Activator As Part of a Health Maintenance Program." Rejuvenation Research. 2011;14(1):45-56. Molgora B, Bateman R, Sweeney G, Finger D, Dimler T, Effros RB, Valenzuela HF. "Functional Assessment of Pharmacological Telomerase Activators in Human T Cells." Cells. 2013;2(1):57-66.
Frequently Asked Questions
What did the 2011 Harley study examine?
The 2011 paper by Harley, Liu, Blasco and colleagues, published in Rejuvenation Research, described a health maintenance program that included a natural product telomerase activator. The study reported on telomere length and immune biomarkers measured in participants over the course of the program. RevGenetics summarizes what the study examined in neutral terms and does not present it as proof of any health or longevity outcome.
What is Dr. Valenzuela's research on telomerase activators?
Dr. Hector Valenzuela, Ph.D., RevGenetics Chief Science Officer, co-authored academic work published in the journal Cells in 2013 that functionally assessed pharmacological telomerase activators in human T cells. The laboratory study examined how Astragalus-derived extracts affected telomerase activity in cultured human immune cells.
Do these studies prove TA-65 has anti-aging benefits?
No. These are published studies that examined telomerase activity, telomere length, and immune cell biomarkers. They do not establish that TA-65 slows, stops, or reverses aging, or that it treats or prevents any disease. RevGenetics reports the research neutrally and makes no such claims.
Where can I find the TA-65 product?
The standardized supplement studied in this space is available as TA-65 (25 mg), a 25 mg Astragalus-derived telomerase activator.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
